8 results about "APPETITE SUPPRESSANTS" patented technology

The invention provides a process for preparing a plasticised superporous hydrogel material comprising subjecting initial hydrogel material to treatment with an acidic solution, an optional treatment with a monovalent metal salt solution, freeze drying and plasticisation. Optionally, the process of the invention produces moulded plasticised superporous hydrogel material bodies that have one or more through-holes formed therein. The plasticised superporous hydrogel material of the present invention may be formulated as a suitable oral dosage form for use an appetite suppressant and for use to deliver a pharmaceutical and / or nutraceutical into a human or animal body.

A composition comprising a soy protein isolate, a soy fibre, a phospholipid, and a carbohydrate for use in the treatment or prevention of obesity, type 2 diabetes or cardiovascular disorders, wherein the composition is administered together with a first pharmaceutical composition comprising an appetite suppressant agent.

The present disclosure provides recombinantly manufactured fusion proteins comprising a GLP-1 protein fragment or an analog thereof linked to a feline Fc fragment. Embodiments include the administration of the fusion proteins to patients and their use as an appetite suppressant, for treatment of obesity, for prevention of obesity, or for treatment of other conditions associated with excess weight in cats. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

Disclosed herein is the use of N6-benzylaminopurine (BAP) as an appetite suppressant in animals including humans. The results of studies demonstrate the use of BAP as an appetite suppressant in animals, and the use of this common agricultural supplement for plant growth can be used to help to alleviate the ever-growing obesity pandemic afflicting modern society.

The present invention aims to provide a food (including foods for specified health uses and foods with functional claims) or pharmaceutical product containing rare sugars as an active ingredient that can be used for novel applications. [Solution] The above problem is achieved by a food composition or pharmaceutical composition containing D-allose, D-sorbose, or derivatives thereof as an active ingredient, for the prevention, improvement, or treatment of symptoms or diseases selected from the group consisting of obesity due to overeating, diabetes or elevated blood glucose levels resulting from obesity due to overeating, and hepatic fat accumulation resulting from obesity due to overeating.

The present disclosure provides recombinantly manufactured fusion proteins comprising a GLP-1 protein fragment or an analog thereof linked to a feline Fc fragment. Embodiments include the administration of the fusion proteins to patients and their use as an appetite suppressant, for treatment of obesity, for prevention of obesity, or for treatment of other conditions associated with excess weight in cats. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

Disclosed herein is the use of N6-benzylaminopurine (BAP) as an appetite suppressant in animals including humans. The results of studies demonstrate the use of BAP as an appetite suppressant in animals, and the use of this common agricultural supplement for plant growth can be used to help to alleviate the ever-growing obesity pandemic afflicting modern society.

The present disclosure provides recombinantly manufactured fusion proteins comprising a GLP-1 protein fragment or an analog thereof linked to a feline Fc fragment. Embodiments include the administration of the fusion proteins to patients and their use as an appetite suppressant, for treatment of obesity, for prevention of obesity, or for treatment of other conditions associated with excess weight in cats. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.